ResultsIQ › Latest results › Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited Q2 FY27 earnings call summary
NSE: SYMBIOTEC · BSE: 544889
Earnings call of 6 Nov 2026, summarised by AI from the filing.
Symbiotec reported Q2 FY27 revenue of ₹280 cr, up 43%, and maintained FY27 guidance of approximately 20% revenue growth and around 25% EBITDA growth.
Key takeaways
- FY27 guidance Management maintains approximately 20% revenue growth and around 25% EBITDA growth for the current fiscal year, with a range of 5% points either side.
- DCV milestone ₹53 cr milestone revenue recognised in Q2 from the US complex injectable agreement, expected to recur year-on-year.
Symbiotec Pharmalab Limited Q2 FY27 results
As filed: Revenue ₹280 cr, EBITDA ₹91.5 cr, PAT ₹51.7 cr, EBITDA margin 32.7%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹280 cr). Scored once a year-earlier consolidated quarter exists.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹211 cr, EBITDA ₹59.2 cr, PAT ₹47.0 cr, EBITDA margin 28.1%. Not scored. No result for the same quarter last year. Share price after the results: +4.5% in 30 days (Nifty 500: −4.5%).
Past price moves after results do not indicate future moves. Not a recommendation.
Symbiotec Pharmalab Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.